Transcriptomics

Dataset Information

0

Expression data from syngeneic Hepa1-6 model in C57Bl/6J mice


ABSTRACT: Lenvatinib is an effective drug in advanced hepatocellular carcinoma (HCC). Its combination with the anti-PD1 immune checkpoint inhibitor pembrolizumab has achieved encouraging results in phase Ib and is currently being tested in phase III trials. Here, we aimed at exploring the molecular and immunomodulatory effects of lenvatinib alone or in combination with anti-PD1. We generated a syngeneic model of HCC in C57BL/6J mice and randomized the animals to receive placebo, lenvatinib, anti-PD1 or combination treatment. Transcriptomic analysis were performed to assess the expression profile of tumors from mice receiving each treatment strategy.

ORGANISM(S): Mus musculus

PROVIDER: GSE153203 | GEO | 2023/04/07

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-08-08 | GSE223201 | GEO
2024-08-04 | GSE181946 | GEO
2024-08-04 | GSE181436 | GEO
2024-08-04 | GSE181947 | GEO
2021-07-22 | GSE157905 | GEO
| 2393260 | ecrin-mdr-crc
2022-06-15 | GSE174770 | GEO
2022-06-15 | GSE174570 | GEO
2023-03-22 | GSE227620 | GEO
2021-09-09 | E-MTAB-11058 | biostudies-arrayexpress